Squarepoint’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Squarepoint’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,816	Closed	-$903K	–	2686
2020 Q1	$903K	Sell	18,816 -34,714	-65%	-$1.61M	0.02%	760
2019 Q4	$2.51M	Buy	+53,530	New	+$2.37M	0.01%	771
2019 Q3	–	Sell	-30,880	Closed	-$929K	–	2836
2019 Q2	$929K	Sell	30,880 -63	-0.2%	-$1.44K	0.01%	1300
2019 Q1	$693K	Sell	30,943 -6,659	-18%	-$143K	0.01%	1299
2018 Q4	$684K	Sell	37,602 -15,597	-29%	-$245K	0.01%	1084
2018 Q3	$962K	Buy	53,199 +37,678	+243%	+$447K	0.01%	1007
2018 Q2	$154K	Buy	+15,521	New	+$107K	﹤0.01%	1585
2018 Q1	–	Sell	-19,592	Closed	-$167K	–	2373
2017 Q4	$167K	Buy	+19,592	New	+$241K	﹤0.01%	1847
2017 Q3	–	Sell	-10,500	Closed	-$197K	–	1998
2017 Q2	$197K	Buy	+10,500	New	+$237K	﹤0.01%	1310

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Squarepoint's RARX Position: Q2 2020 in Review

Squarepoint sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 18,816 shares — an estimated $903K sold.

Squarepoint first reported a position in RARX in Q2 2017 and held it in 9 quarters. The position peaked at $2.51M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Squarepoint reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Squarepoint sold 18,816 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $903K.
Squarepoint first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Squarepoint's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.51M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Squarepoint's 13F filing for Q2 2020, filed 14 Aug 2020.